Tag: pharmaceuticals
-

Covid-19 Vaccine for Lower-Income Regions Underway
Researchers in the U.K. designed a vaccine to prevent Covid-19 infections and is starting an enterprise to make it available to lower-income countries.
-

Infographic – High Hopes for Covid-19 Therapy, Vaccine
Sizeable majorities of Americans expect to see treatments and a vaccine for Covid-19 in the next 12 months, but also another outbreak of the disease.
-

Industry, Univ. Labs Partner on Covid-19 Therapy
Researchers from industry and academic labs are developing a synthetic antibody that in lab tests shows promise as both a Covid-19 therapy and vaccine.
-

MD Anderson to Advance Laser Immunotherapy
An experimental cancer treatment that uses lasers to activate drugs that invoke the immune system is being evaluated by MD Anderson Cancer Center.
-

Fix Discovered for Gene Therapy Virus Delivery
Researchers in France and the U.S. discovered a bacterial enzyme that blocks immune reactions to otherwise benign viruses that deliver gene therapies.
-

Biotechs Apply Crispr Gene-Editing for Hemophilia
A treatment for the blood disease hemophilia and other inherited disorders are being developed with the gene-editing technology Crispr in a biotechnology deal.
-

Covid-19 Antibody Therapy Trial Underway
A clinical trial of neutralizing antibodies to treat Covid-19 infections began testing the therapy with hospitalized patients in New York and Los Angeles.
-

NIH Funds Light-Aided Gene Therapy for Eye Disease
A company creating a gene therapy for age-related macular degeneration activated with near-infrared rays received an NIH grant to advance its technology.
-

Drug Added to Covid-19 Lung Disease Trial
A clinical trial evaluating numerous therapies for a serious lung complication of Covid-19 infections is adding a drug to treat glaucoma to the study.
-

Drug Maker Licenses Low-Dose Vaccine Patch
The pharmaceutical company Merck is licensing a microneedle patch device that delivers vaccines with a small fraction of the dose normally needed by syringes.